|
The Derwent Drug File presents information on all aspects of drug
research and usage.
DDFU selectively covers the worldwide pharmaceutical literature,
papers chosen may cover the chemistry, analysis, pharmaceutics,
pharmacology, metabolism, biochemistry, interactions, therapeutic
effects and toxicity of a drug.
Each document in DDFU contains a detailed abstract written by a
Derwent subject specialist and is accompanied by extensive drug
oriented indexing allowing highly specific retrieval. The Derwent
Drug File will be of particular interest to information specialists
and research scientists working in the pharmaceuticals and health
care industries. DDFU is open to subscribers only. DDNS contains
everything but the extension abstract and is available to all.
Use DDFU/DDNS to research:
- the use of ondansetron to treat cisplatin-induced vomiting.
- the compatibility of ranitidine with antacid preparations.
- structure-activity relationships of pyrimidine nucleoside
anti-HIV agents.
- the use of targeted drug delivery systems for anticancer agents.
- pharmacokinetics of drugs used to treat psoriasis.
Sources:
Papers from over 1,150 scientific and medical journals and
conference proceedings are included. A full list of titles covered
is available from the producer.
AN - Accession number & update
2008-16619 20080526.
TI - Title
Impact of the therapy by renin-angiotensin system targeting
antihypertensive agents perindopril versus telmisartan on
prothrombotic state in essential hypertension.
AU - Author(s)
Remkova-A, Kratochvil'ova-H, Durina-J.
CO - Company name
Univ.Comenius.
LO - Location
Bratislava, Slovakia.
IN - Author affiliation
Comenius Univ, Dept Internal Med, Mickiewiczova 13,
Bratislava, Slovakia, 81369 (Remkova A, e-mail: remkova
@gmailcom).
SO - Source
J-Hum-Hypertens (22, No. 5, 338-45, 2008) Coden: 5567P ISSN:
0950-9240.
YR - Publication year
2008.
LG - Language
EN.
TG - Thematic groups
Therapeutics (T).
SC - Section
58 Vasoactive.
AB - Abstract (A1 A2)
This study investigated the effects of p.o. perindopril
arginine (Prestarium A, Servier) and p.o. telmisartan
(Micardis, Boehr.Ingelheim) on endothelial/platelet function
and coagulation/fibrinolysis in 36 patients with hypertension.
Systolic and diastolic B.P. were reduced or normalized due to
each therapy. A decrease of plasma von Willebrand factor (vWF)
, soluble P-selectin (sPsel), soluble glycoprotein V (sGpV),
plasminogen activator inhibitor type 1 (PAI-1), and tissue
type plasminogen activator (tPA) antigen level after
perindopril therapy was seen. In contrast, a decrease of
plasma soluble endothelial protein C receptor (sEPCR) and
fibrinogen level after therapy by telmisartan. Thus, the
additional beneficial antithrombotic effects of renin-
angiotensin system targeting agents may be important in terms
of the favorable role of antihypertensive drugs in
cardiovascular morbidity.
Methods
36 Patients (aged 26-83 yr, mean 55.8 yr, 11 male) with
hypertension randomly received p.o. perindopril (5 mg/day) (n
=20, mean age 56.9 yr, 6 male) or p.o. telmisartan (40 mg/day)
(n=16, mean age 53.9 yr, 5 male).
Results
There were no differences among all the study groups with
respect to age, sex, obesity, glycemia, HDL cholesterol,
triglyceride, serum creatinine, platelet counts, C-reactive
protein, and chromogranin level. The value of systolic B.P.,
diastolic B.P., total and LDL cholesterol was higher in
hypertensive patients compared with healthy subjects (n=26,
aged 33-75 yr, mean 51.8 yr, 11 male). No changes in systolic
B.P., diastolic B.P., and hemostasis parameters between
hypertensive patients treated by perindopril or telmisartan
neither before therapy nor after therapy were found. In
comparison with healthy subjects, an increase of TM, vWF, s
Psel, sGpV, PAI-1 antigen, tPA antigen, sEPCR, and fibrinogen
level in untreated hypertensive patients was found. A decrease
of the B.P. by perindopril as well as by telmisartan therapy
was achieved. In comparison with the values before therapy, a
decrease in plasma vWF, sPsel, sGpV, PAI-1 antigen, and tPA
antigen after 1 mth of perindopril therapy was found. In
contrast, a decrease of plasma sEPCR and fibrinogen level
after 1 mth of telmisartan therapy was observed. No changes of
serum chromogranin level due to perindopril or telmisartan
therapy were found. (D72).
CT - Common terms
HYPERTENSION/TR; VASCULAR-DISEASE/TR; CASES/FT; IN-VIVO/FT;
ANTIHYPERTENSIVE/FT; SYSTOLIC/FT; BLOOD-PRESSURE/FT; DIASTOLIC
/FT; HEMODYNAMICS/FT.
LT - Link terms
1 OF 2.
*01* TELMISARTAN/TR; BIBR-277/RN; MICARDIS/TR; MICARDIS/TR;
BOEHR-INGELHEIM/FT; ANGIOTENSIN-RECEPTOR-ANTAGONISTS/FT;
HYPOTENSIVES/FT; ANGIOTENSIN-II-AT-1-RECEPTOR-ANTAGONISTS/FT;
ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS/FT; ANGIOTENSIN-2-
ANTAGONISTS/FT; ANGIOTENSIN-ANTAGONISTS/FT; ANGIOTENSIN-II-
AT-1-ANTAGONISTS/FT; TR/FT.
2 OF 2.
*02* PERINDOPRIL ARGININE/TR; DR0200668/RN; SERVIER/FT; ACE-
INHIBITORS/FT; HYPOTENSIVES/FT; VASODILATORS/FT; TR/FT.
NT - Notes
1 Fig. 3 Tab. 46 Ref.
Labels/description Example
AN Accession number 1_: 2008-16619.AN.
& update - see Limit options -
TI Title 2_: ANTIHYPERTENSIVE WITH
ANGIOTENSIN.TI.
AU Author(s) 3_: REMKOVA-A$
CO Company name 4_: COMENIUS.CO.
LO Location 5_: BRATISLAVA.LO.
IN Author affiliation 6_: BRATISLAVA.IN.
SO Source 7_: J-HUM-HYPERTENS.SO.
YR Publication year 8_: YEAR=2008
LG Language 9_: EN.LG.
TG Thematic groups 10_: THERAPEUTICS.TG.
SC Section 11_: VASOACTIVE.SC.
or 12_: 58.SC.
AB Abstract (A1 A2) 13_: PERINDOPRIL WITH
TELMISARTAN
A1 Abstract summary 14_: RENIN WITH ANGIOTENSIN.A1.
A2 Abstract extension 15_: RESULTS SAME TELMISARTAN.A2.
DE Descriptors (CT LT) 16_: HYPERTENSION-TR.CT.
CT Common terms 17_: BLOOD-PRESSURE.CT.
LT Link terms 18_: ANGIOTENSIN-ANTAGONISTS.LT.
19_: 31828-71-4
NT Notes 20_: FIG.NT.
AY= Accession year 1_: AY=2008
YEAR= Publication year 2_: YEAR=2008
LG= Language 3_: LG=EN
TG= Thematic Groups 4_: TG=C
SC= Sections 5_: SC=58
1_: HYPOTENSIVES.DE.
YEAR Publication Year YY 2_: ..L 1 YEAR EQ 2008
UDATE Update date YYYYMMDD 3_: ..L 1 UDATE<20080601
UMONTH Update month YYYYMM 4_: ..L 1 UMONTH WL 200707,200712
AY Accession year YYYY 5_: ..L AY>2006
In the DE paragraph
Animal (A) Y/N 6_: ..L 1 ANIMAL=Y
Human (H) Y/N 7_: ..L 1 H=Y.
By paragraph - author, title: _: ..P AU, TI 1-20
SHORT AN OC TI AU SO
MEDIUM AN OC TI AU SO CO LO IN AB
LONG AN OC TI AU SO CO LO AB DE (CT LT)
ALL AN OC TI AU SO YR CO LO IN LG TG SC AB DE (CT LT) NT
HITS All paragraphs where search terms occur
FREE AN OC TI YR LG TG SC DE (CT LT) NT
_: ..P LONG 5,7-10
* A2 paragraph available in DDFU only.
DE/CT/LT - Descriptors:
A standard name (e.g. INN, USAN, laboratory code) is used to
identify each drug. In addition the pharmacological classification
and the drug activity are also indexed
There are two types of descriptor - Common Terms in the CT field
and Link Terms in the LT field. For most descriptor searches it
is best to qualify to the superlabel DE.
Common Terms (CT) - this contains all those terms that are common to
the whole document. CT may be present in any document where more
than one drug is discussed in the original article. If you know that
the descriptors you are searching are Common Terms then qualify to
CT, otherwise always use DE.
Link Terms (LT) - these are divided into separate indexing fields;
each field containing all the descriptors related to a single drug.
If you know that the descriptors you are searching are Link Terms
then qualify to LT, otherwise always use DE to include any
descriptors that are listed in the Common Terms field.
Always use the SAME operator to link different terms - eg:
CHLOROPROMAZINE SAME PHARMACOKINETICS.DE.
You can use the WITH operator of hyphens to link a descriptor term
to the appropriate drug/disease qualifiers - e.g.:
PARACETAMOL WITH PH.DE.
or:
PARACETAMOL-PH (paragraph qualification not necessary)
This will retrieve documents relating to the pharmacology of
paracetamol.
Drug and Disease Qualifiers:
AE Side effect; toxicity
DI Drug interaction (used for drugs only)
DM Drug metabolism (used for drugs only)
FT Further term
G1-G8 General chemical codes
OC Other context
PH Pharmacology (used for drugs only)
PI Inorganic code/ Physical code
PP Peptide code
RC Reference compound (used for drugs only)
RN Registry name
SS Steroid code
TR Treatment
Search Options:
..SET PLURALS ON and ..SET MEDWORD ON can be selected in DDFU/DDNS
Do not use ..SET PLURALS ON when searching for a specific drug
activity or class.
Guides:
The guide to DDFU is published in the Biomedical Manual, Berne and
online in the BASE database - search BASE-DDFU.
Back to the Datasheet Index Page
© 2009 Dialog LLC All Rights Reserved
|